HRP20040534A2 - Hiv integrase inhibitors - Google Patents

Hiv integrase inhibitors

Info

Publication number
HRP20040534A2
HRP20040534A2 HR20040534A HRP20040534A HRP20040534A2 HR P20040534 A2 HRP20040534 A2 HR P20040534A2 HR 20040534 A HR20040534 A HR 20040534A HR P20040534 A HRP20040534 A HR P20040534A HR P20040534 A2 HRP20040534 A2 HR P20040534A2
Authority
HR
Croatia
Prior art keywords
alkyl
compound
image
aryl
benzyl
Prior art date
Application number
HR20040534A
Other languages
English (en)
Croatian (hr)
Inventor
Banville Jacques
Plamondon Serge
Remillard Roger
A. Walker Michael
Original Assignee
Bristol-Myers Squibb Company A Delaware (Usa) Corp
Oration
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company A Delaware (Usa) Corp, Oration filed Critical Bristol-Myers Squibb Company A Delaware (Usa) Corp
Publication of HRP20040534A2 publication Critical patent/HRP20040534A2/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C207/00Compounds containing nitroso groups bound to a carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C207/00Compounds containing nitroso groups bound to a carbon skeleton
    • C07C207/04Compounds containing nitroso groups bound to a carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08Hydroxylamino compounds or their ethers or esters
    • C07C239/20Hydroxylamino compounds or their ethers or esters having oxygen atoms of hydroxylamino groups etherified
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/63Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C255/64Carboxylic acid nitriles containing cyano groups and nitrogen atoms further bound to other hetero atoms, other than oxygen atoms of nitro or nitroso groups, bound to the same carbon skeleton with the nitrogen atoms further bound to oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HR20040534A 2001-12-12 2004-06-11 Hiv integrase inhibitors HRP20040534A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33967401P 2001-12-12 2001-12-12
PCT/US2002/039092 WO2003049690A2 (en) 2001-12-12 2002-12-06 Hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
HRP20040534A2 true HRP20040534A2 (en) 2005-04-30

Family

ID=23330105

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040534A HRP20040534A2 (en) 2001-12-12 2004-06-11 Hiv integrase inhibitors

Country Status (24)

Country Link
US (1) US6777440B2 (is)
EP (1) EP1467695A2 (is)
JP (1) JP2005515206A (is)
KR (1) KR20040065251A (is)
CN (1) CN1617849A (is)
AR (1) AR037770A1 (is)
AU (1) AU2002366604A1 (is)
BR (1) BR0214842A (is)
CA (1) CA2469592C (is)
CO (1) CO5590909A2 (is)
HR (1) HRP20040534A2 (is)
HU (1) HUP0402675A2 (is)
IL (1) IL162325A0 (is)
IS (1) IS7305A (is)
MX (1) MXPA04005623A (is)
NO (1) NO20042916L (is)
NZ (1) NZ533413A (is)
PE (1) PE20030763A1 (is)
PL (1) PL370664A1 (is)
RU (1) RU2284315C2 (is)
TW (1) TWI252757B (is)
UY (1) UY27577A1 (is)
WO (1) WO2003049690A2 (is)
ZA (1) ZA200404628B (is)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094909B2 (en) 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US7169932B2 (en) 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
PA8586801A1 (es) 2002-10-31 2005-02-04 Pfizer Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
CA2513141A1 (en) 2003-01-27 2004-08-12 Pfizer Inc. Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
US6890942B2 (en) * 2003-05-16 2005-05-10 Bristol-Myers Squibb Company Acyl sulfonamides as inhibitors of HIV integrase
US7776863B2 (en) * 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US20050215544A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
MXPA06012342A (es) 2004-04-26 2007-01-17 Pfizer Inhibidores de la enzima integrasa del virus de la inmunodeficiencia humana.
WO2005103003A2 (en) 2004-04-26 2005-11-03 Pfizer Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
US7507838B2 (en) * 2004-09-01 2009-03-24 Bristol-Myers Squibb Company Process for the preparation of Z-5-carboxymethylene-1,3-dioxolan-4-ones
US20060058286A1 (en) * 2004-09-16 2006-03-16 Mark Krystal Methods of treating HIV infection
WO2007086584A1 (ja) * 2006-01-30 2007-08-02 Meiji Seika Kaisha, Ltd. 新規FabKおよびFabI/K阻害剤
WO2008004100A2 (en) 2006-07-05 2008-01-10 Pfizer Products Inc. Therapeutic compounds
PT2364293E (pt) * 2008-12-05 2013-04-26 Syngenta Participations Ag Novas pirazol-4-n-alcoxicarboxamidas como microbiocidas
US20120316161A1 (en) 2009-12-23 2012-12-13 Katholieke Universiteit Leuven Novel antiviral compounds
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
EP2640705A2 (en) 2010-11-15 2013-09-25 Katholieke Universiteit Leuven Novel antiviral compounds
CN104245660A (zh) * 2012-04-26 2014-12-24 拜尔农科股份公司 制备n-(5-氯-2-异丙基苄基)-环丙胺的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR029304A1 (es) * 1998-06-26 2003-06-25 Daiichi Seiyaku Co DERIVADOS DE PROPIONILO SUSTITUIDOS, PRODUCTO FARMACEUTICO, USO PARA LA FABRICACION DE UNA COMPOSICION FARMACEUTICA PARA LA PREVENCION Y/O TRATAMIENTO DE HIPERCOLESTEROLEMIA, HIPERLIPEMIA O ARTERIOESCLEROSIS, COMPOSICIoN FARMACÉUTICA Y COMPUESTOS INTERMEDIARIOS

Also Published As

Publication number Publication date
NO20042916L (no) 2004-09-10
CA2469592A1 (en) 2003-06-19
ZA200404628B (en) 2005-09-01
CO5590909A2 (es) 2005-12-30
IL162325A0 (en) 2005-11-20
US20030176495A1 (en) 2003-09-18
WO2003049690A3 (en) 2004-01-22
EP1467695A2 (en) 2004-10-20
MXPA04005623A (es) 2004-12-06
CN1617849A (zh) 2005-05-18
AU2002366604A1 (en) 2003-06-23
CA2469592C (en) 2005-08-23
BR0214842A (pt) 2005-01-11
UY27577A1 (es) 2003-07-31
RU2004119963A (ru) 2006-01-10
NZ533413A (en) 2006-09-29
PL370664A1 (en) 2005-05-30
US6777440B2 (en) 2004-08-17
KR20040065251A (ko) 2004-07-21
TW200301105A (en) 2003-07-01
PE20030763A1 (es) 2003-09-13
WO2003049690A2 (en) 2003-06-19
TWI252757B (en) 2006-04-11
JP2005515206A (ja) 2005-05-26
IS7305A (is) 2004-06-10
HUP0402675A2 (hu) 2005-03-29
AR037770A1 (es) 2004-12-01
RU2284315C2 (ru) 2006-09-27

Similar Documents

Publication Publication Date Title
CA2469592C (en) Hiv integrase inhibitors
US7109186B2 (en) HIV integrase inhibitors
JP4528918B2 (ja) カルボキサミド誘導体
US20170326104A1 (en) Ire-1alpha inhibitors
JP2011523956A (ja) 癌の治療のために用いることができる化合物
US20070299114A1 (en) Biaryl Derivatives
AU2001269895B2 (en) Hiv integrase inhibitors
CN102123763A (zh) 富马酸氢甲酯的前体药物、其药物组合物、及其使用方法
CA2838703C (en) Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases
AU2001269895A1 (en) HIV integrase inhibitors
CA2702536A1 (en) Novel histone deacetylase inhibitors
JP2007501280A (ja) 新規医薬組成物を用いた免疫調節
JPH0322869B2 (is)
SK4132003A3 (en) Propionic acid derivatives, the process for their preparation, pharmaceutical composition comprising them, use thereof and intermediates for producing them
US6890942B2 (en) Acyl sulfonamides as inhibitors of HIV integrase
JPH07138214A (ja) 置換アミド酸誘導体
JPH10251224A (ja) 新規なチオカルバミン酸誘導体

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20051115

Year of fee payment: 4

OBST Application withdrawn